Biopharma
Boehringer Ingelheim Strikes Nearly $1B ADC Deal with AimedBio; EyePoint Pharmaceuticals Announces $150M Stock Sale
Boehringer Ingelheim; AimedBio; antibody-drug conjugate; ADC; cancer therapy; biotech licensing deal; EyePoint Pharmaceuticals; stock sale; biopharma funding
Biopharma Deal Activity Shows Uptick in Q3 2025: Signs of Recovery and Emerging Trends
biopharma; Q3 2025; deal activity; M&A; licensing; therapeutic diversification; early-stage assets; China; US; Europe; Metsera; Verona Pharma; Merus; high-value deals
The 5 Most Powerful Women in Biopharma: 2025 News & Key Figures
powerful women; biopharma; female CEO; Reshma Kewalramani; Yvonne Greenstreet; Sarah Boyce; Emma Walmsley; Belén Garijo; leadership
Endpoints News Launches Industry Sentiment Survey, But No Evidence Yet of a New Biopharma Sentiment Index
Endpoints News; biopharma; sentiment; survey; industry trends; John Carroll
Catalent Opens New Global HQ; Fujifilm Launches North Carolina Factory
Catalent; Global Headquarters; Tampa Florida; Fujifilm Biotechnologies; North Carolina; Holly Springs; manufacturing facility; Johnson & Johnson; cell culture; biopharma
Seres Therapeutics Cuts 25% of Workforce Following FDA Feedback on Microbiome Therapy Trial
Seres Therapeutics; layoffs; microbiome; FDA feedback; SER-155; phase 2 trial; workforce reduction; biopharma; clinical studies; cash runway
GSK Commits $30 Billion to Bolster U.S. R&D and Manufacturing
GSK; $30 billion investment; U.S. expansion; R&D; manufacturing; biopharma; supply chain; advanced digital technologies
Atlas Venture Raises $400M Opportunity Fund to Bolster Biotech Portfolio
Atlas Venture; $400M growth fund; biotech startups; Opportunity Fund III; portfolio support; venture capital; late-stage funding; biopharma investment
Endpoints News to Announce 2025 ‘Endpoints 11’ Biotechs to Watch Live in Boston
Endpoints 11; biotech startups; biopharma; Boston; live event; industry trends; biotech innovation
Novartis Again Partners with Argo Biopharma in $5.2B+ RNAi Cardiovascular Deal
Novartis; Argo Biopharma; RNA interference (RNAi); siRNA; cardiovascular pipeline; ANGPTL3; dyslipidemia; biotech collaboration; drug development; milestone payments